Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil
April 22, 2024
Source: drugdu
148
Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes
Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.
Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at their production facility in Nova Lima.
The total addressable market opportunity of Semaglutide in Brazil is approximately $580 million as per the IQVIA MAT Q4 2023.
https://www.expresspharma.in/biocon-signs-licensing-and-supply-pact-with-biomm-s-a-for-semaglutide-commercialisation-in-brazil/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
